Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Alessandra BearzJean-François MartiniJacek JassemSang-We KimGee-Chen ChangAlice T. ShawDeborah A. ShepardElisa Dall’O’Anna PolliHolger ThurmGerard ZalcmanMaria Rosario Garcia CampeloKonstantin PenkovHidetoshi HayashiBenjamin J. Solomon2026-02-032026-02-032023-1110.1016/j.jtho.2023.07.023https://scholars.csmu.edu.tw/handle/123456789/4861[SDGs]SDG3Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutationsjournal-article